The Impact of Early Versus Late Platelet and Neutrophil Recovery after Induction Chemotherapy on Survival Outcomes of Patients with Acute Myeloid Leukemia

• Published in: Turkish journal of haematology Vol. 37; no. 2; pp. 116 - 120
• Main Authors: Çiftçiler, Rafiye, Haznedaroğlu, İbrahim C., Sayınalp, Nilgün, Özcebe, Osman, Aksu, Salih, Demiroğlu, Haluk, Göker, Hakan, Malkan, Ümit Yavuz, Büyükaşık, Yahya
• Format: Journal Article
• Language: English
• Published: Turkey Türk Hematoloji Derneği 01-01-2020; Galenos Publishing House; Galenos Publishing
• Subjects: acute myeloid leukemia; Brief Report; Chemotherapy; Leukemia; Medical prognosis; neutrophil recovery; Neutrophils; platelet recovery; Tıp; İstanbul; Türkiye; Neutrophil recovery; Acute myeloid leukemia; Platelet recovery; Nötrofil iyileşmesi; Akut myeloid lösemi; Trombosit iyileşmesi
• ISSN: 1300-7777; 1308-5263
• DOI: 10.4274/tjh.galenos.2019.2019.0154

The prognosis of patients with acute myeloid leukemia (AML) is affected by factors that are both patient- and disease-specific. The aim of this study is to evaluate the impact of early versus late platelet and neutrophil recovery after induction chemotherapy on survival outcomes of AML patients.
A total of 181 patients with AML who were treated in our tertiary center between 2001 and 2018 were evaluated. Neutrophil and platelet recovery times were accepted as the periods from the beginning of induction chemotherapy to a neutrophil count of ≥0.5x10
/L and a platelet count of ≥20x10
/L 3 days in a row, respectively. The median time to platelet recovery was 25 days (range=12-52) for all patients. Therefore, platelet recovery in the first 25 days was defined as early platelet recovery (EPR) and at ≥26 days it was defined as late platelet recovery (LPR). The median time to neutrophil recovery was 28 days (range=13-51) for all patients. Therefore, neutrophil recovery in the first 28 days was defined as early neutrophil recovery, and at ≥29 days it was defined as late neutrophil recovery.
The 5-year overall survival (OS) rates for patients who had EPR and LPR after induction chemotherapy were 62% and 23%, respectively (p<0.001). The 5-year disease-free survival (DFS) rates for patients who had EPR and LPR after induction chemotherapy were 57% and 15%, respectively (p<0.001).
Short bone marrow recovery time may indicate better healthy hematopoiesis and marrow capacity associated with longer OS and DFS.